Showing results (31-40 of 4,830) with videos related to
Sort By:
Pageof 483
Expert Opinion on Drug Safety|February 25, 2022
Safety of current antiviral drugs for chronic hepatitis BChiara Masetti, Nicola Pugliese, Alessio Aghemo, et al.Hepatology (Baltimore, Md.)|February 15, 2011
Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis CLuca Valenti, Mariagrazia Rumi, Enrico Galmozzi, et al.Clinics and Research in Hepatology and Gastroenterology|March 26, 2011
Does interferon therapy prevent hepatocellular carcinoma in patients with chronic viral hepatitis?Elena Vezali, Alessio Aghemo, Pietro Lampertico, et al.Journal of Autoimmunity|March 14, 2019
The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicineLorenza Rimassa, Nicola Personeni, Alessio Aghemo, et al.Current Opinion in Virology|April 19, 2017
Direct-acting antivirals: the endgame for hepatitis C?Roberta D'Ambrosio, Elisabetta Degasperi, Massimo Colombo, et al.Techniques and Innovations in Gastrointestinal Endoscopy|February 1, 2021
Stay (GI) Healthy: COVID-19 and Gastrointestinal ManifestationsEdoardo Vespa, Nicola Pugliese, Francesca Colapietro, et al.Best Practice & Research. Clinical Gastroenterology|December 13, 2016
Surveillance for hepatocellular carcinomaÁlvaro Díaz-González, Alejandro FornerPlos One|August 30, 2014
Interaction between PNPLA3 I148M variant and age at infection in determining fibrosis progression in chronic hepatitis CStella De Nicola, Paola Dongiovanni, Alessio Aghemo, et al.Clinical and Molecular Hepatology|May 3, 2019
Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failureTommaso Lorenzo Parigi, Maria Corina Plaz Torres, Alessio AghemoPageof 483